Servatus Ltd CEO and founder, Dr Wayne Finlayson, to speak at Pharmabiotics Conference 2021

20 April 2021

Dr Wayne Finlayson, Servatus’ CEO and co-founder, is scheduled to give a presentation on ‘developing a new class of autoimmune drugs’ at the Pharmabiotics 2021 conference on 28th & 29th April, and will be covering the innovative research and drug development currently undertaken by Servatus Ltd.

Dr Wayne Finlayson, Servatus’ CEO and co-founder, is scheduled to give a presentation on ‘developing a new class of autoimmune drugs’ at the Pharmabiotics 2021 conference next week. The conference is due to take place as an online virtual gathering on April 28th & 29th 2021 (due to COVID-19 related travel restrictions) and will host many world leading scientists and key stakeholders in the human microbiome-live bacterial therapeutics space. The conference will cover many relevant topics such as the latest microbiome research and its role in human health, microbiome diagnostic tools and clinical end points, company updates from leading biotherapeutic industry partners, and round table discussions with key industry stakeholders. Wayne’s presentation will be covering the innovative research and drug development currently undertaken by Servatus Ltd, including the latest updates on Servatus’ current and upcoming clinical trials. Servatus has a number of clinical trials underway for indications such as H.pylori infection, chronic functional constipation, ulcerative colitis, and Rheumatoid Arthritis. Servatus is an Australian based biotechnology company which develops and produces live bacterial biotherapeutic drugs; said to be the next pharmaceutical frontier of western medicine.

The Pharmabiotics conference takes place annually and is the brainchild of the Pharmabiotics Research Institute (PRI) of Europe, which is a not-for-profit collaborative effort to drive the accessibility of live biological products to the pharmaceutical market. The PRI states that it believes that “the microbiome is the future of human medicine”. However, as scientific research, industry, and innovation often outpace regulation, the development of these new biological-based medicines represents a huge paradigm shift for current regulatory frameworks. All products intended to prevent or treat disease need to be registered as medicinal products to reach market in the US, Australia, and Europe. Therefore, compliance to the biological medicinal product legislative and regulatory framework is critically important for the industry. The PRI was founded to make this transition to the pharmaceutical market easier, by facilitating the conversation between drug regulators and bacterial-based drug developers, like Servatus.

For more information on the pharmabiotics conference or to register to attend see:

https://www.pharmabioticsevent.com/

For more on Servatus’ research and clinical pipelines see: www.servatus.com.au